Adagene Inc.

ADAGSEC EDGAR

Pharmaceutical Preparations(E9)CIK: 1818838

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$9.3M	$10.2M	$700.9K	$480.0K	$1.5M
Research and Development Expense	$81.3M	$68.1M	$33.5M	$16.2M	$16.1M
Operating Income (Loss)	-$83.9M	-$72.4M	-$43.2M	-$19.2M	-$17.3M
Interest Expense	—	$363.8K	$202.2K	$138.1K	$91.1K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$79.5M	-$71.5M	-$42.4M	-$16.4M	-$15.3M
Income Tax Expense (Benefit)	$459.1K	$1.7M	$1.7M	$1.7M	—
Net Income (Loss) Attributable to Parent	-$80.0M	-$73.2M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$115.7M	$152.4M	$189.5M	$84.3M	$105.9M
Assets, Current	$113.4M	$149.3M	$186.0M	$79.1M	$103.9M
Cash and Cash Equivalents, at Carrying Value	$109.9M	$143.8M	$174.4M	$75.2M	$92.5M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$3.0M	$3.0M	$480.0K
Liabilities	$45.2M	$69.3M	$33.0M	$19.2M	$8.7M
Liabilities, Current	$31.5M	$55.1M	$29.8M	$16.1M	$7.2M
Long-term Debt, Excluding Current Maturities	$13.5M	$14.1M	$3.0M	$3.0M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$48.6M	-$43.4M	-$28.5M	-$18.2M	-$14.3M
Net Cash Provided by (Used in) Investing Activities	-$686.0K	-$2.5M	$7.1M	$24.9M	-$29.5M
Net Cash Provided by (Used in) Financing Activities	$17.8M	$145.4M	$4.4M	$69.7M	$51.1M
Payments for Repurchase of Common Stock	$4.0M	$2.4M	$2.4M	$2.4M	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)